Stand-alone transcriptional immune response prediction in primary triple-negative breast cancer
Triple-negative breast cancer (TNBC) accounts for 10-20% of primary breast cancers and often has early relapses and aggressive progression. An activated tumour immune response can be prognostic in treatment-naive and chemotherapy-treated TNBC patients and may be assessed using gene expression data. We derived a stand-alone predictor for a proposed immunomodulatory transcriptional TNBC subtype in a
